Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Upgraded by ValuEngine to “Hold”

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday, September 1st.

Several other analysts have also issued reports on the company. HC Wainwright started coverage on Concert Pharmaceuticals in a report on Monday, July 24th. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research lowered Concert Pharmaceuticals from a “buy” rating to a “sell” rating in a research note on Monday, May 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price objective (down from $31.00) on shares of Concert Pharmaceuticals in a research note on Monday, July 10th. Aegis reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Concert Pharmaceuticals in a research note on Monday, June 12th. Finally, BidaskClub lowered Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.80.

Concert Pharmaceuticals (CNCE) traded down 1.02% during trading on Friday, hitting $14.58. 130,695 shares of the stock were exchanged. The firm’s market cap is $330.78 million. Concert Pharmaceuticals has a 12-month low of $7.11 and a 12-month high of $19.11. The stock’s 50-day moving average price is $14.61 and its 200-day moving average price is $14.82.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. On average, equities analysts expect that Concert Pharmaceuticals will post ($2.18) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Upgraded by ValuEngine to “Hold”” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2017/09/16/concert-pharmaceuticals-inc-cnce-upgraded-to-hold-at-valuengine.html.

Several large investors have recently made changes to their positions in CNCE. Fisher Asset Management LLC boosted its position in shares of Concert Pharmaceuticals by 22.7% during the first quarter. Fisher Asset Management LLC now owns 44,363 shares of the biotechnology company’s stock valued at $757,000 after buying an additional 8,200 shares during the last quarter. Rockefeller Financial Services Inc. boosted its position in Concert Pharmaceuticals by 19.6% in the first quarter. Rockefeller Financial Services Inc. now owns 10,289 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 1,689 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Concert Pharmaceuticals by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 124,144 shares of the biotechnology company’s stock worth $2,118,000 after purchasing an additional 4,873 shares during the last quarter. Virginia Retirement Systems ET AL boosted its position in Concert Pharmaceuticals by 186.6% in the first quarter. Virginia Retirement Systems ET AL now owns 51,300 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 33,400 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in Concert Pharmaceuticals in the first quarter worth $143,000. 62.37% of the stock is currently owned by institutional investors.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply